9mzz

Crystal structure of RIPK1 with compound 36

spinqualitylabelsall models 9mzz, resolution 2.68Å Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Structural highlights 9mzz is a 2 chain structure with sequence from Homo sapiens. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance. Method: X-ray diffraction, Resolution 2.68Å Ligands: A1BU5, IOD Resources: FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT Function RIPK1_HUMAN Serine-threonine kinase which transduces inflammatory and cell-death signals (programmed necrosis) following death receptors ligation, activation of pathogen recognition receptors (PRRs), and DNA damage. Upon activation of TNFR1 by the TNF-alpha family cytokines, TRADD and TRAF2 are recruited to the receptor. Ubiquitination by TRAF2 via 'Lys-63'-link chains acts as a critical enhancer of communication with downstream signal transducers in the mitogen-activated protein kinase pathway and the NF-kappa-B pathway, which in turn mediate downstream events including the activation of genes encoding inflammatory molecules. Polyubiquitinated protein binds to IKBKG/NEMO, the regulatory subunit of the IKK complex, a critical event for NF-kappa-B activation. Interaction with other cellular RHIM-containing adapters initiates gene activation and cell death. RIPK1 and RIPK3 association, in particular, forms a necrosis-inducing complex. Publication Abstract from PubMed Receptor-interacting protein kinase 1 (RIPK1) plays an essential role in necroptosis, a form of inflammatory, caspase-independent, programmed cell death. Allosteric inhibitors of RIPK1 have been shown to block necroptotic cell death and thus may offer potential therapeutic opportunities across a range of infectious, autoimmune, and neurodegenerative diseases. We report the structure-informed discovery of a novel series of bridged benzoazepine amides as part of our efforts to develop a CNS-penetrant small-molecule inhibitor of RIPK1 with a low projected oral human dose. The Discovery of Bridged Benzoazepine Amides as Selective Allosteric Modulators of RIPK1.,Chen JL, Methot JL, Mitcheltree MJ, Musacchio A, Corcoran EB, Feng G, Lammens A, Maskos K, Palte RL, Rickard MM, Otte KM, Mansueto MS, Venkat S, Sondey C, Thomsen M, Lesburg CA, Fradera X, Fell MJ, DiMauro EF, Siliphaivanh P ACS Med Chem Lett. 2025 Apr 14;16(5):811-818. doi: , 10.1021/acsmedchemlett.5c00063. eCollection 2025 May 8. PMID:40365380 From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Proteopedia Page Contributors and Editors (what is this?)

OCA